Article
Oncology
Shuri Aoki, Hiroshi Onishi, Masataka Karube, Naoyoshi Yamamoto, Hideomi Yamashita, Yoshiyuki Shioyama, Yasuo Matsumoto, Yukinori Matsuo, Akifumi Miyakawa, Haruo Matsushita, Hitoshi Ishikawa
Summary: This retrospective study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) and carbon ion radiotherapy (CIRT) in elderly patients with non-small-cell lung cancer (NSCLC) using Japanese multicenter data. The study found that SBRT and CIRT showed similar survival and local control rates in elderly patients, but CIRT was associated with a lower incidence of radiation pneumonitis.
Article
Oncology
Tithi Biswas, Afshin Dowlati, Charles A. Kunos, John J. Pink, Nancy L. Oleinick, Shakun Malik, Pingfu Fu, Shufen Cao, Debora S. Bruno, David L. Bajor, Monaliben Patel, Stanton L. Gerson, Mitchell Machtay
Summary: The combination of TRC102 with pemetrexed, cisplatin, and radiotherapy in NS-NSCLC patients is safe and well tolerated, and it shows good treatment response and progression-free survival in some patients.
CLINICAL CANCER RESEARCH
(2022)
Review
Medicine, General & Internal
Alesha A. Thai, Benjamin J. Solomon, Lecia Sequist, Justin F. Gainor, Rebecca S. Heist
Summary: The seminar highlights significant advancements in screening, diagnosis, and treatment of lung cancer in the past two decades, with a specific focus on targeted therapies and immune checkpoint inhibitors. These progressions have transformed outcomes for many patients.
Article
Oncology
Percy Lee, Billy W. Loo Jr, Tithi Biswas, George X. Ding, Issam M. El Naqa, Andrew Jackson, Feng-Ming Kong, Tamara LaCouture, Moyed Miften, Timothy Solberg, Wolfgang A. Tome, An Tai, Ellen Yorke, X. Allen Li
Summary: Based on the evaluation of published experiences with SBRT, a steep dose-response relationship exists with high rates of durable local control for early-stage non-small cell lung cancer when physical doses of 43-50 Gy are delivered.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Jessika Contreras, Amar Srivastava, Pamela Samson, Todd DeWees, Ramaswamy Govindan, Maria Q. Baggstrom, Daniel Morgensztern, Michael Roach, Shahed N. Badiyan, Jeffrey Bradley, Saiama Waqar, Clifford Robinson
Summary: The study aimed to evaluate the maximum tolerated dose of hypofractionated proton beam radiation therapy with concurrent weekly carboplatin/paclitaxel in patients with stage II-III non-small cell lung cancer. The results showed that the treatment was acutely well tolerated, with high rates of locoregional control and overall survival. Late serious adverse events were noted in some patients outside of the dose-escalation window.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
A. S. Fung, D. M. Graham, E. X. Chen, T. L. Stockley, T. Zhang, L. W. Le, H. Albaba, K. M. Pisters, P. A. Bradbury, M. Trinkaus, M. Chan, S. Arif, U. Zurawska, J. Rothenstein, D. Zawisza, S. Effendi, S. Gill, M. Sawczak, J. H. Law, N. B. Leighl
Summary: The combination of binimetinib with carboplatin and pemetrexed appears to have manageable toxicity and evidence of activity in advanced non-squamous NSCLC.
Article
Pharmacology & Pharmacy
Nikki de Rouw, Merel de Boer, Rene J. Boosman, Michel M. van den Heuvel, David M. Burger, Joris E. Lieverse, Hieronymus J. Derijks, Geert W. J. Frederix, Rob ter Heine
Summary: This study investigates the costs and benefits of individualized dosing of pemetrexed in reducing the incidence of neutropenia. The results show that individualized dosing can lead to significant cost savings and decreased risk of neutropenia-related hospitalization or death.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Joel R. Eisner, Gregory M. Mayhew, James M. Davison, Kirk D. Beebe, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jeffrey M. Conroy, Michael Milburn, David Neil Hayes, Kathryn F. Mileham
Summary: The Piedmont study evaluated the application of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NS-NSCLC) treated with PMX-PDC. The study found that AF-PRS can help identify patients who have a positive response to PMX-PDC treatment. This study provides clinical evidence supporting AF-PRS as a potential diagnostic test.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Esengul Kocak Uzel, Melisa Bagci Kilic, Hasan Morcali, Omer Uzel
Summary: This study retrospectively analyzed the outcomes of operable patients with early-stage NSCLC who underwent SBRT after refusing surgery. The results suggest that SBRT can be an effective and well-tolerated alternative for operable early-stage NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Nasser Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller, Hong-Liang Lim, Christopher Desch, Klara Szondy, Radj Gervais, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn
Summary: The study aimed to compare the efficacy and toxicity of pemetrexed and docetaxel in patients with advanced non-small-cell lung cancer previously treated with chemotherapy. The results showed that both pemetrexed and docetaxel had low overall response rates and there was no significant difference in progression-free survival and overall survival between the two drugs. However, pemetrexed had significantly fewer side effects compared to docetaxel and should be considered as a standard treatment option for second-line non-small-cell lung cancer when available.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yang-Gun Suh, Jae Myoung Noh, Doo Yeul Lee, Tae Hyun Kim, Unurjargal Bayasgalan, Hongryull Pyo, Sung Ho Moon
Summary: Proton beam therapy (PBT) was compared with photon radiotherapy for stage I non-small cell lung cancer (NSCLC) in terms of clinical outcomes and dosimetry. Data from patients who underwent PBT or photon radiotherapy at two Korean institutions were analyzed. Multivariate Cox proportional hazards models and propensity score-matched analyses were used to compare local progression-free survival (PFS) and overall survival (OS). Survival and radiation exposure to the lungs were compared in the matched population. Of the 289 patients included, 112 underwent PBT and 177 underwent photon radiotherapy. With a median follow-up of 27 months, the 2-year local PFS and OS rates were 94.0% and 83.0%, respectively. Multivariate analysis showed a biologically effective dose (BED10, using alpha/beta = 10 Gy) of >= 125 cobalt gray equivalents was significantly associated with improved local PFS and OS. In the matched analyses, the local PFS and OS did not differ between groups. However, PBT showed significantly lower lung and heart radiation exposure in terms of mean dose, V5, and V10 compared to photon radiotherapy. PBT reduced radiation exposure to the heart and lungs without worsening disease control in stage I NSCLC patients.
Article
Oncology
Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Haruhiro Saito, Tetsuro Kondo, Kazuo Nishikawa, Satoshi Otsu, Akihiro Bessho, Hiroshi Tanaka, Hiroyuki Yamaguchi, Takayuki Kaburagi, Hisao Imai, Keita Mori, Junya Ohtake, Hiroaki Okamoto
Summary: The addition of bevacizumab to cisplatin and pemetrexed combination therapy as maintenance treatment prolongs progression-free survival in patients with untreated, advanced, non-squamous NSCLC. Early response to induction therapy and pretreatment monocytic myeloid-derived suppressor cell counts may be associated with the survival benefit of adding bevacizumab.
Article
Infectious Diseases
Chaw-Ning Lee, Frank Po-Chao Chiu, Chao-Kai Hsu
Summary: Early recognition of cutaneous cytomegalovirus (CMV) infection is crucial, especially for end-stage cancer patients receiving tyrosine kinase inhibitors (TKIs). It is important to remain vigilant for the potential life-threatening viral infection that may masquerade as a side effect of treatment drugs.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Oncology
Nobuteru Kubo, Hiroaki Suefuji, Mio Nakajima, Sunao Tokumaru, Naoko Okano, Daisaku Yoshida, Osamu Suzuki, Hitoshi Ishikawa, Miyako Satouchi, Haruhiko Nakayama, Yoshiyuki Shioyama
Summary: This nationwide registry study in Japan provides real-world treatment outcomes of carbon-ion radiation therapy (CIRT) for inoperable stage I non-small cell lung cancer (NSCLC). The most common CIRT schedule was 60 Gy (relative biological effectiveness (RBE)) in four fractions, and the 3-year overall survival rate was 59.3%. Female sex and ECOG performance status of 0-1 were favorable prognostic factors for overall survival. Therefore, CIRT is an effective option for treating inoperable stage I NSCLC.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Medicine, General & Internal
Marco Mueller, Jeremy Booth, Adam Briggs, Dasantha Jayamanne, Vanessa Panettieri, Sashendra Senthi, Chun-Chien Shieh, Paul Keall
Summary: This study introduces a markerless tumor tracking technique for accurate and optimal radiotherapy. The feasibility of this technique will be investigated through an interventional trial, and the accuracy will be evaluated using implanted fiducial markers.
Article
Oncology
Yuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue, Yuka Fujita, Ryo Toyozawa, Tomoki Kimura, Kosuke Takahashi, Kazuo Nishikawa, Junji Kishimoto, Yoichi Nakanishi, Isamu Okamoto
Article
Oncology
Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Takeshi Kitazaki, Katsumi Nakatomi, Seiji Nagashima, Masaaki Fukuda, Akitoshi Kinoshita, Hiroshi Soda, Hiroshi Mukae
Article
Oncology
Yasuhiro Tanaka, Hiroshi Soda, Yuichi Fukuda, Kenta Nio, Sawana Ono, Hiromi Tomono, Midori Shimada, Masataka Yoshida, Tatsuhiko Harada, Asuka Umemura, Keisuke Iwasaki, Hiroyuki Yamaguchi, Hiroshi Mukae
Article
Medicine, General & Internal
Hiroshi Gyotoku, Hiroyuki Yamaguchi, Hiroshi Ishimoto, Shuntaro Sato, Hirokazu Taniguchi, Hiroaki Senju, Tomoyuki Kakugawa, Katsumi Nakatomi, Noriho Sakamoto, Minoru Fukuda, Yasushi Obase, Hiroshi Soda, Kazuto Ashizawa, Hiroshi Mukae
JOURNAL OF CLINICAL MEDICINE
(2020)
Review
Medicine, General & Internal
Fumiko Hayashi, Takashi Kido, Noriho Sakamoto, Yoshiaki Zaizen, Mutsumi Ozasa, Mitsuru Yokoyama, Hirokazu Yura, Atsuko Hara, Hiroshi Ishimoto, Hiroyuki Yamaguchi, Taiga Miyazaki, Yasushi Obase, Yuji Ishimatsu, Yoshinobu Eishi, Junya Fukuoka, Hiroshi Mukae
MEDICINA-LITHUANIA
(2020)
Article
Oncology
Yosuke Dotsu, Minoru Fukuda, Noritaka Honda, Hiroshi Gyotoku, Yoshihisa Kohno, Takayuki Suyama, Yasuhiro Umeyama, Hirokazu Taniguchi, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae
Summary: The combination therapy of dabrafenib and trametinib for BRAF V600E-mutant non-small cell lung cancer showed strong antitumor effects in an elderly patient, despite leading to relatively severe adverse events. The significant tumor shrinkage prolonged the patient's life and maintained a good general condition, indicating that targeted therapy may be considered with appropriate drug dose reduction even in extremely old patients.
Article
Oncology
Shinnosuke Takemoto, Kazumasa Akagi, Sawana Ono, Hiromi Tomono, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Daiki Ogawara, Hiroaki Senju, Hiroshi Gyotoku, Nanae Sugasaki, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Hiroshi Mukae
Summary: This study aimed to evaluate the treatment effect of S-1 following PEM-containing treatment in patients with NSCLC. The results showed that the overall response rate of S-1 after PEM in NSCLC patients was low.
Article
Medicine, General & Internal
Yosuke Dotsu, Hiroyuki Yamaguchi, Minoru Fukuda, Takayuki Suyama, Noritaka Honda, Yasuhiro Umeyama, Hirokazu Taniguchi, Hiroshi Gyotoku, Shinnosuke Takemoto, Ryuta Tagawa, Ryosuke Ogata, Hiromi Tomono, Midori Shimada, Hiroaki Senju, Katsumi Nakatomi, Seiji Nagashima, Hiroshi Soda, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae
Summary: This study examined the real-world incidence of febrile neutropenia among patients with thoracic malignancies treated with single-agent amrubicin chemotherapy, and found that the incidence rate was 30%. It suggests that prophylactic G-CSF should be administered during practical use of this chemotherapy regimen for patients who have already undergone chemotherapy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Satomi Tanaka, Junji Uchino, Takashi Yokoi, Takashi Kijima, Yasuhiro Goto, Yoshifumi Suga, Yuki Katayama, Ryota Nakamura, Kenji Morimoto, Akira Nakao, Makoto Hibino, Nozomi Tani, Takayuki Takeda, Hiroyuki Yamaguchi, Yusuke Tachibana, Chieko Takumi, Noriya Hiraoka, Masafumi Takeshita, Keisuke Onoi, Yusuke Chihara, Ryusuke Taniguchi, Takahiro Yamada, Yohei Matsui, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama
Summary: Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies is more effective than cytotoxic chemotherapies alone in advanced NSCLC patients. The prognostic nutritional index (PNI) and lung immune prognostic index (LIPI) may serve as prognostic markers for chemoimmunotherapy.
Article
Oncology
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Takashi Mizowaki, Yoshio Monzen, Takaya Ikeda, Seiji Nagashima, Yutaro Tasaki, Daisuke Nakamura, Kazutoshi Komiya, Katsumi Nakatomi, Eisuke Sasaki, Koichi Hirakawa, Hiroshi Mukae
Summary: This study aims to investigate the efficacy and toxicities of amrubicin plus cisplatin combined with concurrent accelerated hyperfractionated thoracic radiotherapy in the treatment of unresectable limited-disease small cell lung cancer patients.
Article
Oncology
Hirokazu Taniguchi, Kazumasa Akagi, Yosuke Dotsu, Tadaaki Yamada, Sawana Ono, Erika Imamura, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Triparna Sen, Seiji Yano, Hiroshi Mukae
Summary: This study investigated the molecular mechanisms of acquired resistance to lorlatinib in ALK-rearranged lung cancer cells. It was found that the resistant cells did not harbor secondary ALK mutations, but overexpressed HER3 protein and NRG1 ligand. Inhibiting HER3 or silencing HER3 gene resensitized the resistant cells to lorlatinib. Targeting NRG1/HER3 may be a potential novel therapeutic option for lorlatinib-resistant ALK-rearranged lung cancer.
Article
Medicine, General & Internal
Yasuhiro Tanaka, Kazuko Yamamoto, Shimpei Morimoto, Takeshi Nabeshima, Kayoko Matsushima, Hiroshi Ishimoto, Nobuyuki Ashizawa, Tatsuro Hirayama, Kazuaki Takeda, Hiroshi Gyotoku, Naoki Iwanaga, Shinnosuke Takemoto, Susumu Fukahori, Takahiro Takazono, Hiroyuki Yamaguchi, Takashi Kido, Noriho Sakamoto, Naoki Hosogaya, Shogo Akabame, Takashi Sugimoto, Hirotomo Yamanashi, Kosuke Matsui, Mai Izumida, Ayumi Fujita, Masato Tashiro, Takeshi Tanaka, Koya Ariyoshi, Akitsugu Furumoto, Kouichi Morita, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae
Summary: This study investigated the outcomes of Japanese patients with mild COVID-19 and identified risk factors associated with hospitalization during isolation. The findings suggest that 80% of mild COVID-19 patients can safely isolate at home.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Respiratory System
Hiroshi Ishimoto, Noriho Sakamoto, Mutsumi Ozasa, Shin Tsutsui, Atsuko Hara, Takashi Kido, Hiroyuki Yamaguchi, Kazuko Yamamoto, Yasushi Obase, Yuji Ishimatsu, Hiroshi Mukae
Summary: A 60-year-old Japanese man with a history of heavy smoking presented to the hospital with gradually worsening dyspnea, and was diagnosed with desquamative interstitial pneumonia using transbronchial lung cryobiopsy. This is the first detailed report of such diagnosis.
RESPIRATORY MEDICINE CASE REPORTS
(2021)
Article
Medicine, General & Internal
Noriho Sakamoto, Shintaro Hara, Hiroshi Ishimoto, Shota Nakashima, Hirokazu Yura, Takuto Miyamura, Daisuke Okuno, Atsuko Hara, Tomoyuki Kakugawa, Hiroyuki Yamaguchi, Yasushi Obase, Hisako Kushima, Hiroshi Ishii, Shingo Noguchi, Takashi Kido, Tsutomu Kobayashi, Yoshifumi Soejima, Sumako Yoshioka, Yuji Ishimatsu, Kazuhiro Yatera, Jun-ichi Kadota, Hiroshi Mukae
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
(2019)
Article
Oncology
Masashi Nishimura, Yoshifumi Kimizuka, Takunori Ogawa, Motohiro Tsuchiya, Yoshiki Kato, Akira Matsukida, Shunya Igarashi, Koki Ito, Yusuke Serizawa, Tomomi Tanigaki, Yuji Fujikura, Yuka Katsurada, Sho Ogata, Akihiko Kawana
Summary: This study reports a case of IgG4-related retroperitoneal fibrosis occurring after chemotherapy. The patient showed improvement after discontinuing immunotherapy and receiving steroid treatment.
Article
Oncology
Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda
Summary: This study aimed to investigate the clinicopathological differences and therapeutic response of NSCLC patients with SDC4::ROS1 fusion to crizotinib. The study found that different ROS1 fusion partners may affect the efficacy of crizotinib and patient prognosis. In addition, higher expression levels of ROS1 and pERK1/2 in tumor cells of case 2 may be related to the therapeutic response and prognosis.
Review
Oncology
Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu
Summary: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Over the past decade, immunotherapy has made progress in the treatment of SCLC, but current immune checkpoint inhibitors have limited benefits for patient survival. Therefore, it is important to explore new targets and develop drugs with novel mechanisms for immunotherapy in SCLC.
Article
Oncology
Kazuto Sugai, Kojiro Nakaoka, Rika Tobita, Shinji Kikuchi, Kei Inoue, Midori Enokido, Moriyuki Kiyoshima
Summary: This article presents a case of multilocular mediastinal cyst leading to the development of thymic cancer. Resection of multilocular anterior mediastinal cysts should be considered due to the challenges in preoperative diagnosis, the potential for coexisting tumors with cysts, and the risk of malignant tumor development.
